SCHEMBL18325670

SCHEMBL18325670

CC(=O)CCCCCC(=O)Nc1nc(=O)[nH]cc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XDH P47989 1/20 0.39
PARP1 P09874 3/20 0.37
HDAC1 Q13547 7/20 0.35
HDAC6 Q9UBN7 4/20 0.35
HDAC9 Q9UKV0 2/20 0.35
HDAC2 Q92769 6/20 0.35
HDAC3 O15379 4/20 0.35
CYP3A4 P08684 1/20 0.35
PAOX Q6QHF9 1/20 0.35
HDAC8 Q9BY41 3/20 0.35
LMNA P02545 2/20 0.35
POLB P06746 1/20 0.35
ABL1 P00519 2/20 0.34
RIN1 Q13671 2/20 0.34
SPHK2 Q9NRA0 1/20 0.34
SPHK1 Q9NYA1 1/20 0.34
NSD2 O96028 1/20 0.34
RORC P51449 1/20 0.34
NCOR2 Q9Y618 1/20 0.34
HDAC4 P56524 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18325610 0.89 XDH (0.50) XDHLMNAPOLBSPHK2SPHK1
SCHEMBL7905802 0.87 HDAC1 (0.49) HDAC1HDAC6HDAC9HDAC2HDAC3
SCHEMBL1225985 0.77 GDA (0.36) LMNAABL1
SCHEMBL11926260 0.75 LMNA (0.30) LMNA
SCHEMBL7063733 0.70 ALDH1A1 (0.43) CYP3A4POLBKMT2A
SCHEMBL31260667 0.70 ALDH1A1 (0.45) POLBKMT2A
SCHEMBL7063685 0.69 LMNA (0.51) XDHLMNA
SCHEMBL7064550 0.69 LMNA (0.47) XDHLMNAKMT2A
SCHEMBL18325718 0.68 MAT2A (0.37) XDHLMNA
SCHEMBL12104083 0.68 HDAC1 (0.43) HDAC1HDAC6HDAC9HDAC2HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016203337-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER MOHAN M ALAPATI (IN) 2016-12-22 WO disclosed
WO-2016203352-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER MOHAN M ALAPATI (IN) 2016-12-22 WO disclosed